HC Wainwright Forecasts Arvinas’ Q3 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Arvinas in a report issued on Wednesday, August 5th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.20) for the quarter, down from their previous forecast of ($1.02). The consensus estimate for Arvinas’ current full-year earnings is ($2.39) per share. HC Wainwright also issued estimates for Arvinas’ Q4 2026 earnings at ($1.19) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($3.55) EPS, FY2029 earnings at ($1.16) EPS and FY2030 earnings at $0.07 EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $2.95. The firm had revenue of $249.70 million for the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.During the same quarter in the previous year, the business earned ($0.84) EPS. The company’s quarterly revenue was up 1014.7% compared to the same quarter last year.

Other equities research analysts have also issued reports about the stock. BTIG Research reiterated a “buy” rating and set a $18.00 price target on shares of Arvinas in a research note on Tuesday. Zacks Research raised Arvinas from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Barclays lifted their price objective on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Citigroup boosted their price objective on shares of Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $11.00 price objective (down from $15.00) on shares of Arvinas in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $14.90.

Arvinas Trading Up 3.3%

NASDAQ:ARVN opened at $8.68 on Friday. The stock has a fifty day moving average price of $8.06 and a 200 day moving average price of $10.25. The firm has a market cap of $560.03 million, a PE ratio of 86.81 and a beta of 1.71. Arvinas has a 12-month low of $6.05 and a 12-month high of $14.51.

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after buying an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board increased its position in Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after purchasing an additional 3,500 shares in the last quarter. Abel Hall LLC acquired a new position in Arvinas in the 4th quarter valued at about $125,000. Corient Private Wealth LLC acquired a new position in Arvinas in the 4th quarter valued at about $127,000. Finally, Jain Global LLC purchased a new position in Arvinas in the 3rd quarter valued at about $95,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Insider Transactions at Arvinas

In related news, CFO Andrew Saik sold 11,139 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the sale, the chief financial officer owned 193,128 shares in the company, valued at $1,919,692.32. This represents a 5.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,413.52. Following the sale, the insider owned 191,395 shares in the company, valued at approximately $1,902,466.30. The trade was a 5.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 41,728 shares of company stock valued at $402,649 in the last ninety days. 7.30% of the stock is currently owned by company insiders.

Key Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas received a Zacks Rank #1 (Strong Buy), reflecting improved expectations for its earnings outlook and potentially supporting near-term buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS forecast to a loss of $0.67 from a loss of $3.98, while also improving estimates for FY2027 through FY2030. Its FY2030 forecast moved into profitability at $0.07 per share, suggesting better long-term operating prospects. Arvinas Analyst Estimates
• Positive Sentiment: BTIG Research assigned Arvinas a “Buy” rating, adding to the bullish analyst support. Arvinas Earns Buy Rating from BTIG
• Positive Sentiment: Arvinas’ latest quarterly results substantially exceeded expectations, with $249.7 million in revenue versus a $60.7 million consensus estimate and EPS of $2.58 versus an expected loss. Revenue increased more than tenfold year over year, providing a strong fundamental backdrop. Arvinas Trading Higher on Strong Earnings
• Neutral Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS forecasts to losses of $1.20 and $1.19, respectively, but raised most full-year estimates. The mixed revisions indicate near-term profitability remains pressured even as the longer-term outlook improves.
• Negative Sentiment: Wells Fargo downgraded Arvinas to “Equal Weight,” signaling reduced conviction in additional upside and contributing to selling pressure. Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: Shares fell sharply following an analyst downgrade, highlighting the stock’s sensitivity to changes in Wall Street sentiment. Arvinas Shares Down on Analyst Downgrade

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.